Back to Directory
NN1177 (Amycretin)
Metabolic & Weight ManagementNovel GLP-1/amylin co-agonist showing exceptional weight loss in early trials.
Key Benefits
- ✓Exceptional weight loss (13% at 12 weeks)
- ✓Single molecule dual agonist
- ✓GLP-1 and amylin benefits
- ✓Potential best-in-class efficacy
Dosing Information
Dosage Range
Under investigation
Frequency
Weekly
Typical Duration
Phase 2 trials
Detailed Protocol
Under development. Administered via subcutaneous injection weekly in trials. Phase 2 trials ongoing.
About NN1177 (Amycretin)
Amycretin (NN1177) is a single molecule that co-agonizes GLP-1 and amylin receptors. Early trials showed 13.1% weight loss at 12 weeks, projecting to potentially 25%+ at longer duration. Being developed by Novo Nordisk.
Research Notes
Phase 1/2 data showed 13.1% weight loss at just 12 weeks, suggesting potential for 25%+ with longer treatment. Exciting early data. Development ongoing.
Potential Side Effects
- •Nausea and vomiting
- •GI side effects
- •Investigational
Always consult with a healthcare professional before starting any peptide therapy.